Cancer Biomarkers Market 2015 - Global Forecasts to 2020 for the $15 Billion Industry


Dublin, Sept. 14, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/829d3z/cancer_biomarkers) has announced the addition of the "Cancer Biomarkers Market by Tumor, Type , Profiling Technology, Application & Geography - Global Forecast to 2020" report to their offering.

This market is expected to grow at a CAGR of 11.6% from 2015 to 2020

Factors such as rising incidence of cancer; technological advancements in omics technologies; favorable government funding for cancer research; increased demand for personalized medicines in cancer therapies; and increased use of biomarkers in drug discovery development and clinical trials are expected to fuel the growth of the cancer biomarkers market during the forecast period. However, poorly suited regulatory and reimbursement systems of biomarker tests, high capital investments for biomarker discovery and development, and sample collection and storage difficulties are restraining the growth of this market.

The global cancer biomarkers market is segmented on the basis of type of biomarkers, tumor type, profiling technologies, applications, and geography. Based on type, the market is segmented into protein biomarkers, genetic biomarkers, and others which include viral, cell, and carbohydrate biomarkers.

Based on tumor type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, cervical cancer, and other type of cancers such as Gastrointestinal Stromal Tumors (GIST), lung, ovarian, bladder, pancreatic, kidney, melanoma, and leukemia.

Based on profiling technologies, the market is segmented into omics technologies, imaging technologies, immunoassays, cytogenetics, and bioinformatics.

Based on applications, the market is segmented into diagnostics, drug discovery and development, prognostics, risk assessment, and others which include surrogate endpoints, recurrence, personalized medicine, and therapeutics.

The Asia-Pacific market is poised to register the highest growth rate in the forecast period owing to the favorable government funding for cancer biomarker research, rising prevalence of cancer, increasing demand for advanced healthcare facilities in developing economies such as India and China, increasing number of clinical trials, and increasing focus of international players in emerging markets. The global cancer biomarkers market is consolidated in nature at the top. In order to maintain their market shares, leading players are continuously focusing on new product developments and upgrading their existing products to enhance their product portfolios. Increasing competition among major players is expected to drive innovation in the market, thereby helping the industry to overcome existing challenges in various applications such as diagnostics, drug discovery and development, personalized medicine, among others.

Major players in this market are Abbott Laboratories (U.S.), Affymetrix Inc. (U.S.), Roche Diagnostics Ltd. (Switzerland), Illumina, Inc. (U.S.), Qiagen NV (Netherlands), Agilent Technologies (U.S.), Thermo Fisher Scientific Inc. (U.S.), Merck & Co. Inc. (U.S.), Becton Dickinson and Company (U.S.), and Hologic Inc. (U.S.).


Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Industry Trends

7 By Tumor Type

8 Cancer Biomarkers Market, By Type

9 By Profiling Technologies

10 By Application

11 By Geographic Analysis

12 Competitive Landscape

13 Company Profiles

- Abbott Laboratories
- Affymetrix, Inc.
- Agilent Technologies, Inc.
- Becton, Dickinson and Company
- Hologic, Inc.
- Illumina, Inc.
- Merck & Co. Inc.
- Qiagen N.V.
- Quest Diagnostics Inc.
- Roche Diagnostics Ltd.

For more information visit http://www.researchandmarkets.com/research/829d3z/cancer_biomarkers



            

Contact Data

GlobeNewswire

Recommended Reading